Lifeward

Lifeward FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Lifeward (LFWD) as of Oct 8, 2026 is 84.57 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 75.04 % — a change of 12.71% (higher).

FCF Conversion

84.57 %

YoY

12.71%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Lifeward is 2025 84.57 % . FCF Conversion Rate (FCF/EBITDA) of Lifeward was 2024 75.04 % . It decreases by 12.71% higher compared to the previous year.

The Lifeward FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
68.22 USD
Jan 1, 2019
95.41 USD
Jan 1, 2020
97.58 USD
Jan 1, 2021
90.42 USD
Jan 1, 2022
91.55 USD
Jan 1, 2023
93.74 USD
Jan 1, 2024
75.04 USD
Jan 1, 2025
84.57 USD
The Lifeward FCF Conversion history
YEARFCF ConversionYoY
84.57 %+12.71%
75.04 %-19.95%
93.74 %+2.39%
91.55 %+1.25%
90.42 %-7.34%
97.58 %+2.28%
95.41 %+39.85%
68.22 %-25.12%
91.11 %+5.80%
86.11 %-15.05%
101.37 %+56.41%
64.81 %—
Access this data via the Eulerpool API

Lifeward Stock analysis

What does Lifeward do? Rewalk Robotics Ltd is a publicly traded company specializing in the development and manufacture of exoskeletons that enable individuals with spinal injuries or paralysis to regain mobility. It was founded in 2001 and is based in Marlborough, Massachusetts. The company's goal is to provide individuals with mobility impairments the opportunity for greater freedom of movement and improved quality of life. Rewalk Robotics has launched various products in the field of rehabilitation and industrial applications, and it continues to research and develop new applications for its technology. The exoskeletons use a combination of motors, sensors, and control systems to allow users to stand, walk, and even climb stairs. In addition to medical applications, Rewalk Robotics also provides exoskeletons for industrial use, enhancing worker safety and productivity. The company is actively involved in research and development to expand the therapeutic possibilities of exoskeletons for neurologic conditions such as stroke and Parkinson's disease. Rewalk Robotics is dedicated to innovation and technology, aiming to improve the lives of millions worldwide by providing greater mobility and autonomy. Lifeward is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lifeward stock

FCF Conversion Rate (FCF/EBITDA) of Lifeward is 84.57 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Lifeward changed from 75.04 % to 84.57 %, representing a 12.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Lifeward since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Lifeward with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Lifeward

All Key Metrics — Lifeward